Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea–based cohort study
Authors' conclusion
This study suggests that the risk of breast cancer is increased by drugs in the CEPM group but not by tibolone, oral estrogen, CEPP, or topical estrogen. The mortality rate from breast cancer is lower with MHT (tibolone, CEPM, oral estrogen) than without MHT.
Study context
- Population
- Postmenopausal women over 40 years of age, 2003–2011, followed up until 2019; HISK cohort
- Exposure
- Menopausal hormone therapy (MHT) by type vs no MHT
- Outcome
- Risk of breast cancer
Methodological detailspopulation-based, National Health Insurance Database in South Korea (HISK)
- Population-based
- National Health Insurance Database in South Korea (HISK)
Main finding
As reported in the abstract
Breast cancer risk
Each group vs Non-MHTHazard ratio (95% CI)P value
CEPM
1.439(1.374–1.507)
P < 0.001Tibolone
0.968(0.925–1.012)
Oral estrogen
1.002(0.929–1.081)
CEPP
0.929(0.75–1.15)
Topical estrogen
1.139(0.809–1.603)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Breast cancer mortalityTibolonevs Non-MHT | 0.504 (0.432–0.588) | ||
| Breast cancer mortalityCEPMvs Non-MHT | 0.429 (0.352–0.522) | ||
| Breast cancer mortalityOral estrogenvs Non-MHT | 0.453 (0.349–0.588) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
Breast cancer mortality
- Breast cancer mortality lower with MHT vs non-MHT
Original publication
Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea–based cohort study. Eur J Endocrinol. Published 21 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →